期刊文献+

体外循环中应用中低温含血停跳液诱导停跳的心肌保护作用 被引量:4

The clinic study of myocardial protection with hypothermia warm blood cardioplegia in exreacorporeal circulation.
下载PDF
导出
摘要 目的 比较温血心肌停跳液与冷晶体心肌停跳液在心脏瓣膜置换术中的心肌保护作用 ;评价体外循环间断温血停跳的心肌保护价值。方法 在24例心脏瓣膜置换术中分别采用温血灌注 (Ⅰ组 )和冷晶体灌注 (Ⅱ组 ) :每组各12例 ,进行心肌保护临床观察。Ⅰ组先用4 :1温血停跳液灌注心脏停跳 ,以后每隔20min用冷血停跳液灌注一次 ,保持心肌低温 ,在心脏复跳前再用温血灌注。Ⅱ组为应用4℃冷晶体心肌停跳液灌注 ,每隔20min灌注1次。结果 I组心脏自动复跳率明显高于Ⅱ组 (P<0.01) ,术后低心排征发生率明显低于Ⅱ组(P<0.05) ,术后应用心肌正性药物量及时间明显少于Ⅱ组 (P<0.05)。在停机时和停机6h ,Ⅰ组心肌肌钙蛋白明显低于Ⅱ组 (P<0.05) ,24h后心肌磷酸激酶CK,I组明显低于Ⅱ组 (P<0.05)。结论 Objective To compare the different effect of myocardial protection with warm blood cardioplegia and cold crystalloid cardioplegia during the valve replacement operations and to evaluate the myocardial protection of intermittent warm blood cardioplegia. Methods In order to observe the myocardial protection,24patients of valve veplacement operations were divided into two groups:patients of group1(n=12)were perfused with4:1warm blood cardioplegia to make cardioplegia firstly,then4℃cold crystalloid cardioplegia was perfused every20min to keep myocardial hypothermia and warm blood cardioplegia was perfused before heart rebeat.patients of groupⅡ(n=12)were perfused with4℃cold crystalloid cardioplegia and reperfused with it20minutes intervals. Results The heart automatic rebeatic rate in group I was significantly higher than those of groupⅡ(P<0.01).The post-operative incidence of lowcardiac output was signficantly lower than those of groupⅡ(P<0.05).The dosage and time of inotropic drug were significantly less than groupⅡ(P<0.05)Plasma levels of cTnT of group I were obviously lower than those of groupⅡat immediately and6hours after CPB(P<0.05).CK levels of group I were lower than those of group II after reperfusion for24hours(P<0.05) Conclusion Warm blood cardioplegia could provide better myocardial protection than cold crystalloid cardioplegia.
机构地区 杭州市中医院
出处 《浙江临床医学》 2003年第12期895-896,共2页 Zhejiang Clinical Medical Journal
关键词 体外循环 低温含血停跳液 心肌保护 手术 临床资料 心肌细胞 Warm blood cardioplegia Cold crystalloid cardioplegia Cardiopulmonary by pass Myocardial protection
  • 相关文献

参考文献4

二级参考文献1

共引文献30

同被引文献25

  • 1吴歆,王斌,顾熊飞.人红细胞保护蛋白对羟基自由基的清除作用[J].中国生化药物杂志,2004,25(5):297-299. 被引量:2
  • 2李桂芬,王仕刚,胡强,刘迎龙,龙村,赵红.康斯特保护液对未成熟心肌保护效果的临床观察[J].中国体外循环杂志,2006,4(1):9-11. 被引量:15
  • 3李颖,丛晓强,陈丽娟,王雅环.几种生化标志物在评价心肌损伤中的作用[J].中国心血管病研究,2006,4(9):711-713. 被引量:5
  • 4潘柏申,杨振华,吴健民.冠状动脉疾病和心力衰竭时心脏标志物临床检测应用建议[J].中华检验医学杂志,2006,29(9):774-778. 被引量:73
  • 5Kronon MT,Allen BS,Hernan J,et al.Superiority of magnesium cardioplegia in neonatal myocardial protection[J].Ann Thorac Sury,1999,68(6):2285-2291.
  • 6Toyoda Y,Yamaguchi M,Yoshimura Naoki,et al.Cardioprotective effects and the mechanisms of terminal warm blood cardioplegia in pediatric cardiac surgery[J].J Thorac Cardiovasc Surg,2003,125(6):1242-1251.
  • 7Mauney MC,Kron IL.The physiologic basis of warm cardioplegia[J].Ann Thorac surg,1995,60(3):819-823.
  • 8Hoffman JW Jr,Gilbert TB,Poston RS,et al.Myocardial reperfusion injury:etiology,mechanisms,and therapies[J].J Extra Corpor Technol,2004,36(4):391-411.
  • 9Kronon MT,Allen BS,Hernan J,et al.Superiority of magnesium cardioplegia in neonatal myocardial protection.Ann Thorac Sury,1999,68:285-291.
  • 10Toyoda Y,Yamaguchi M,Yoshlmura N,et al.Cardioprotective effects and the mechanisms of terminal wsrm blood cardioplegia in pediatric cardiec surgery.J Thorac Cardiovasc Surg,2003,125:1242-1249.

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部